Warning: ini_set() has been disabled for security reasons in /home/elite/public_html/wp-includes/default-constants.php on line 64
June 11, 2021 - Page 8 of 13 - Elite Stock Chat

Day: June 11, 2021

XOM – Exxon (XOM) Sees US Shale Oil Production Decline Per Well

Exxon Mobil Corporation (XOM Free Report) has been generating fewer barrels of oil from the prolific shale fields of the United States since 2019, per Reuters.

According to a latest report, the company’s oil wells, which are involved in some of the most promising shale fields, produced fewer barrels of oil per well despite an increase in overall expenditure and production.

In 2017, Exxon, which is one of the largest shale oil producers, acquired $6.6 billion of net acres in New Mexico, which doubled the company’s assets in the Permian basin that spans west Texas and New Mexico. Notably, the company intends to boost shale output in the New Mexico portion of the Permian basin to 700,000 barrels per day (bpd) by 2025.

Per data released by the Institute for Energy Economics and Financial Analysis (“IEEFA”), Exxon’s average liquid output for the first 12 months of a well dropped to 521 bpd in 2019 from an average of 635 bpd in 2018 in its Delaware basin assets of New Mexico.

Notably, the company went down to the sixth place from the first on a per-well production basis, falling behind a group of publicly traded producers like Occidental Petroleum Corporation (OXY Free Report) and EOG Resources, Inc. (EOG Free Report) . Full data for 2020 is currently unavailable but initial findings suggest that the company’s Delaware wells continued to lag.

However, in March, Exxon reported that its per-well profits in the New Mexico operations remained steady between 2018 and 2020. Moreover, its Permian assets have met or exceeded its volume projections per year for six years.

The company, which is also involved in the Midland portion of the Permian basin, ranked 12th out of 20 in 2019, based on an output measure that normalizes for well length. Importantly, its average production over a well’s first 12 months improved between 2018 and 2019.

According to the data released by IEEFA, Exxon’s shortfall in production per well came as oil output in the Permian basin grew by an average of about 5%. Although U.S. shale production in the Permian improved significantly last decade, it has slowed in recent years as oil companies focus on profit over output. However, most analysts opine that the company’s actual production is not living up to what they seem to be claiming.

Company Profile & Price Performance

Headquartered in Irving, TX, ExxonMobil is one of the leading integrated energy companies in the world.

Shares of the company have outperformed the industry in the past six months. The stock has gained 48.7% compared with the industry’s 24.5% growth.

Zacks Investment ResearchImage Source: Zacks Investment Research


Zacks Rank & Stock to Consider

The company currently carries a Zack Rank #3 (Hold).

One better-ranked player in the energy space is Whiting Petroleum Corporation (WLL Free Report) , currently flaunting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, the Zacks Consensus Estimate for Whiting Petroleum’s 2021 earnings has been raised by 134.9%.

+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities

In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.

Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.

Click here to download this report FREE >>

AMC – Why AMC Stock Bounced Back on Friday

What happened

Shares of AMC Entertainment Holdings (NYSE:AMC) are bouncing back from their Thursday sell-off, rising 3.4% through 9:40 a.m. EDT today.

The reason: This morning, S&P Global Ratings upgraded the stock’s credit from CCC+ to CCC-.

AMC movie theater.

Image source: AMC Entertainment.

So what

That may sound like bad news. (Shouldn’t “minus” be worse than “plus,” after all?) But in fact, the move is a two-step upgrade from AMC’s previous rating, and indicates that the credit rating agency is a bit more confident today than it was yesterday about AMC’s ability to eventually repay its more than $11 billion debt load.

To do this, says the agency, AMC must apply the cash it has gained from stock sales to pay down some of its debt, refinance the rest at lower interest rates, and benefit from higher revenue as moviegoers return to its theaters.

If all of that happens, says the credit agency, AMC may have “a path to a sustainable capital future.”  

Now what

Three points need to be added to the above, however. First, obviously, this is a lot to ask of poor AMC. It was hobbled by a pandemic, and against all odds emerged from the recession without declaring bankruptcy — but burdened with a boatload of debt.

Second, CCC- is not as bad a credit rating as CCC+, but it’s still a junk bond rating. Don’t make more of this news than it is.

Third and finally: The stock sales that S&P says AMC is depending upon to even start repaying its debt have inflated the company’s share count by a factor of five, compared to the end of 2019. Even if the company succeeds in paying down its debt, it’s that much less profit each individual shareholder can expect to earn from AMC.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

QDEL – Bear of the Day: Quidel (QDEL)

I last wrote about Quidel (QDEL Free Report) as the Bear of the Day on April 30 right before their quarterly report on May 6 that may have helped put a bottom in shares near $100.

But the reason that QDEL remains a Zacks #5 Rank is due to the new round of downward EPS revisions by Wall Street analysts.

In just the past few weeks since that report, the full-year consensus for 2021 has dropped a whopping 30% from $23.22 to $16.28.  

And prior to the company’s Q1 earnings miss and reality-check, that profit projection stood at $28.15.

Why Were Investors and Analysts So Surprised?

Quidel is a $5 billion maker of medical diagnostics that vaulted to unprecedented success during the height of demand for COVID-19 testing kits.

Quidel discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women’s health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis.

Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia and infectious mononucleosis.

Sales vaulted over $1 billion — nearly 200% — last year for their rapid COVID-19 test.

Here’s what I wrote in April…

And I was one investor who was captivated by the story, believing that not only would such testing demand persist but also that the new influx of cash flow would enable this small company to expand many of its R&D and product avenues in diagnostics.

In fact, we took gains of 64% and 48% in the past few quarters riding the wave of demand for testing, and buying the dips when others doubted the sustainability of those sales.

But the fable would not last. And as much as I wanted to believe in the $5 billion company sustaining a new valuation above $10 billion, the revenue growth disappointments from the company and the downward estimate revisions from analysts kept coming in.

In the past few months, the EPS consensus among four Wall Street analysts covering the company has dropped 33% from $39 to $26.

(end of excerpt from my April article)

While many investors (myself included) believed that COVID-19 testing would be a constant part of our lives as travel and shopping attempted a return to normal this spring, the spike in QDEL sales led to a hard reversal.

Current top-line estimates are for an 11% drop to $1.5 billion this year and another 23.5% decline to $1.13B next year.

QDEL remains an innovative diagnostics company with BIG potential for M&A/partnership interest from Big Pharma. But until the estimates stop going down, and start heading back up, the stock is still untouchable.

The Zacks Rank will let you know.

Infrastructure Stock Boom to Sweep America

A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.

The only question is “Will you get into the right stocks early when their growth potential is greatest?”

Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.

Download FREE: How to Profit from Trillions on Spending for Infrastructure >>

SANW –  S&W to Participate in Panel Discussion “Next Generation Seed Companies that are Changing Agriculture” at the Lytham Partners Summer 2021 Investor Conference

LONGMONT, Colo., June 11, 2021 /PRNewswire/ — S&W Seed Company (Nasdaq: SANW) today announced that the Company’s CEO, Mark Wong, will be participating in a panel at the Lytham Partners Summer 2021 Investor Conference titled “Next Generation Seed Companies that are Changing Agriculture.” The panel, to be conducted virtually, will be held on Tuesday, June 15, 2021 at 11:00am ET.

To access the panel, please visit: https://wsw.com/webcast/lytham/panel3/2191917.

Management will also be participating in virtual one-on-one meetings throughout the event, which runs from June 14, 2021 through June 16, 2021. To arrange a meeting, please contact Lytham Partners at [email protected] or register at www.lythampartners.com/summer2021invreg.

About S&W Seed Company

Founded in 1980, S&W Seed Company is a global integrated seed technology company focused on middle market crops. Headquartered in the United States and with operations in Australia, S&W’s vision is to be the world’s preferred proprietary seed Company which supplies a range of forage and specialty crop products that supports the growing global demand for animal proteins and healthier consumer diets. S&W is a global leader in proprietary alfalfa, sorghum and pasture seeds, with significant research and development, production and distribution capabilities. S&W’s product portfolio also includes hybrid sunflower and wheat and the company is utilizing its research and breeding expertise to develop and produce stevia, the all-natural, zero calorie sweetener for the food and beverage industry. For more information, please visit www.swseedco.com.

SOURCE S&W Seed Company

Related Links


MCHX – Marchex to Participate in the Northland Customer Engagement SaaS Conference

SEATTLE–()–Marchex, Inc. (NASDAQ: MCHX), a leading provider of conversational analytics and solutions that connects the voice of the customer to your business, announced today that members of the Marchex management team will participate in the following conference:

2021 Northland Capital Markets Customer Engagement SaaS Conference

Date: Wednesday, June 16th

Presentation Time: 10:30am PT, Fireside Chat

The live audio webcast of the Marchex presentation will be available by visiting the Event Calendar in the Investor Relations section of the Marchex website (http://investors.marchex.com/event-calendar). An archived version of the webcast will be available four hours after the completion of the presentation.

About Marchex

Marchex understands the best customers are those who call your company – they convert faster, buy more, and churn less. Marchex provides solutions that help companies drive more calls, understand what happens on those calls, and convert more of those callers into customers. Our actionable intelligence strengthens the connection between companies and their customers, bridging the physical and digital world, to help brands maximize their marketing investments and operating efficiencies to acquire the best customers.

Please visit www.marchex.com, www.marchex.com/blog or @marchex on Twitter (Twitter.com/Marchex), where Marchex discloses material information from time to time about the company, its financial information, and its business.

TMUS – T-Mobile US, Inc. to Present at the Credit Suisse 23rd Annual Communications Conference

BELLEVUE, Wash.–()–Peter Osvaldik, executive vice president & chief financial officer of T-Mobile US, Inc. (NASDAQ: TMUS), will present and provide a business update on Tuesday, June 15, 2021 at 4:35 p.m. Eastern Daylight Time (EDT) at the Credit Suisse 23rd Annual Communications Conference.

A live webcast of the virtual event will be available on the Company’s Investor Relations website at http://investor.t-mobile.com. An on-demand replay will be available shortly after the conclusion of the presentation.

To automatically receive T-Mobile financial news by e-mail, please visit the T-Mobile Investor Relations website, http://investor.t-mobile.com, and subscribe to E-mail Alerts.

About T-Mobile US, Inc.

T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile and Metro by T-Mobile. For more information please visit: http://www.t-mobile.com.

SNES – SenesTech to Present at the Lytham Partners Summer 2021 Investor Conference

PHOENIX, June 11, 2021 /PRNewswire/ — SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, announced today that it will present at the Lytham Partners Spring 2021 Investor Conference on Tuesday, June 15, 2021 at 11:45am ET.

A webcast of the presentation will be available on the Company’s website at https://senestech.investorroom.com/. The webcast will also be archived and available for replay following the live event.

Management will also be participating in virtual one-on-one meetings throughout the event, which runs from June 14, 2021 through June 16, 2021. To arrange a meeting, please contact Lytham Partners at [email protected] or register at www.lythampartners.com/summer2021invreg.

About SenesTech
SenesTech is changing the model for pest management by targeting one of the root causes of the problem: reproduction.

ContraPest® is an innovative technology with an approach that targets the reproductive capabilities of both sexes in rat populations, inducing egg loss in female rats and impairing sperm development in males. Using a proprietary bait delivery method, ContraPest® is dispensed in a highly palatable liquid formulation that promotes sustained consumption by rat communities. ContraPest® is designed, formulated and dispensed to be low hazard for handlers and non-target species such as wildlife, livestock and pets, where the active ingredients break down rapidly.

We believe ContraPest® will establish a new paradigm in rodent control, resulting in a decreased reliance on lethal options. For more information visit the SenesTech website at www.senestech.com.

Safe Harbor Statement
The foregoing paragraphs contain forward-looking statements that involve estimates, assumptions, risks and uncertainties. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. “Forward-looking statements” may be preceded by words such as “may,” “future,” “plan” or “planned,” “will,” “should,” “expected,” “anticipates,” “continue,” “eventually,” “believes,” or “projected.” Forward-looking statements include statements concerning the potential impact and effects of the COVID-19 pandemic on the Company’s business, results of operations and financial performance; any measures the Company has and may take in response to COVID-19 and any expectations the Company may have with respect thereto; the Company’s strategy and target marketing and markets; continuing the Company’s vision; expected benefits of the Company’s initiatives and continuation of those initiatives; deployment of the Company’s product; the continuation or expansion of the use of ContraPest; demand for ContraPest; the Company’s expectation regarding costs, expenses and cash and continuing its cost improvement plan; future financial results; and the Company’s execution of its strategic business plan.


Investor: Robert Blum, Lytham Partners, LLC, 602-889-9700, [email protected]

Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143

SOURCE SenesTech, Inc.

Related Links


CNST – Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib

  • Translational data support the disease-modifying potential of pelabresib
  • Central pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment
  • Impact of pelabresib treatment observed across a wide range of myelofibrosis patient subgroups

CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) — Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that three posters relating to the MANIFEST clinical trial of pelabresib (CPI-0610) in myelofibrosis (MF) were published online in association with the European Hematology Association (EHA) annual meeting. The data in these posters are based on a data cutoff of September 29, 2020 from the MANIFEST Phase 2 clinical trial and reflect an analysis of pelabresib clinical and translational activity.  

“We are particularly enthusiastic about the publication of centrally reviewed translational data, which describe early improvements in bone marrow fibrosis in patients treated with pelabresib, and we believe these results support our thesis of disease-modifying treatment effects that go beyond symptom management,” said Patrick Trojer, chief scientific officer of Constellation Pharmaceuticals. “We are currently enrolling patients in the Phase 3 pivotal study of MANIFEST-2 and our goal is to transform the standard of care for the treatment of myelofibrosis.”

Data Highlights

Translational data, across all three arms of the Phase 2 MANIFEST study, support the disease-modifying potential of pelabresib

  • Centrally reviewed bone marrow fibrosis (BMF) pathology conducted in 63 patients showed similar improvements as reported previously for local review of BMF grade. 23 out of 63 patients (37%) achieved at least a 1 grade improvement in BMF. Of these patients, 83% achieved improvements in BMF by 24 weeks.
  • 17% of the patients with BMF improvement (4 out of 23), improved by at least 2 grades.
  • 31 out of 63 patients (49%) were stabilized or had no change, and only 4 out of 63 patients (6%) worsened.
  • An increase in BM erythroid progenitor cells and reduction of the number and cluster formation of megakaryocytes in the BM was observed in 59% and 65%, respectively, of 37 samples from patients treated with pelabresib either as a monotherapy or in combination with ruxolitinib.
  • Pelabresib durably reduced inflammatory cytokines such as tumor necrosis factor alpha (TNF alpha) and interleukin 18 (IL18) as early as 2 weeks and maintained through 24 weeks of treatment, based on an analysis of patient samples.

Arm 3 (1L) – CPI-0610 + ruxolitinib interim efficacy subgroup analysis in JAK-inhibitor-naïve patients

  • As previously reported at ASH 2020, 42 of 63 evaluable patients (67%) achieved a ≥35% reduction in spleen volume (SVR35) at 24 weeks (the primary endpoint for Arm 3). 34 of 60 evaluable patients (57%) achieved a ≥50% reduction in Total Symptom Scores (TSS50) at 24 weeks.
  • Strong response was observed with pelabresib, irrespective of baseline risk status or demographic and disease characteristics.
  • Central pathology review of 27 1L patient bone marrow samples showed at least a one-grade improvement in bone marrow fibrosis in 9 out of 27 patients (33%); in all of these patients, improvement was observed within 6 months of starting treatment. 16 out of 27 patients (59%) showed stabilization of bone marrow fibrosis, while only 1 out of 27 patients (4%) showed worsening.

Arm 1 and 2 (2L) – Interim analysis demonstrating that pelabresib monotherapy in JAK-inhibitor-experienced or -ineligible patients, and with pelabresib + ruxolitinib in ruxolitinib-experienced patients, resulted in improvements in anemia

  • As previously reported at ASH 2020, 3 of 14 evaluable Transfusion Dependent (TD) patients (21%) in Arm 1A achieved transfusion independence (the primary endpoint for arms 1A and 2A) and 13 of 36 evaluable TD patients (36%) in Arm 2A achieved transfusion independence.  
  • 9 out of 15 evaluable TD patients (60%) in Arm 1A, and 25 out of 47 of evaluable TD patients (53%) in Arm 2A achieved a ≥50% reduction in red blood cell transfusions.


As of the September 29, 2020 data cutoff, pelabresib was generally well tolerated in MANIFEST, both as monotherapy and in combination with ruxolitinib, and in both JAK-inhibitor-naïve and -ineligible as well as JAK-inhibitor-experienced patients.

Among the most common treatment-emergent adverse events (TEAEs) for CPI-0610 monotherapy in 46 safety-evaluable patients in Arm 1, those that were Grade 3 were thrombocytopenia (15%), anemia (13%), diarrhea (4%), constipation (2%), respiratory tract infection (2%), and weight decrease (2%). Amongst the most common TEAEs, there were no Grade 4. Other Grade 3/4 TEAEs (≥5%) include hyperuricemia (9%), hyperkalemia (7%) and dyspnea (7%). Nine patients discontinued treatment because of TEAEs. No Grade 5 events were observed.

Among the most common TEAEs in 78 safety-evaluable patients in Arm 2, those that were Grade 3 were thrombocytopenia (23%), anemia (10%), respiratory tract infections (5%), diarrhea (4%), asthenic conditions (4%), and nausea (3%). Amongst the most common TEAEs, Grade 4 events included thrombocytopenia (3%) and anemia (1%). Nine patients discontinued treatment due to TEAEs, including six Grade 5 TEAEs, which were acute kidney injury, traumatic subdural hematoma, brain stem hemorrhage (no concomitant thrombocytopenia), disease progression, congestive heart failure, and transformation to AML.

Among the most common TEAEs in 78 safety-evaluable patients in Arm 3, those that were Grade 3 were anemia (28%) and thrombocytopenia (5%). Amongst the most common TEAEs, Grade 4 events included thrombocytopenia (3%), anemia (1%), and respiratory tract infection (1%). Two patients discontinued treatment due to TEAEs. In addition, there were two Grade 5 TEAEs, each resulting from multi-organ failure due to sepsis.

EHA Poster Presentations

TITLE: Pelabresib (CPI-0610) improved anemia associated with myelofibrosis: interim results from MANIFEST Phase 2 study (Abstract Code: EP1077) 

TITLE: Clinical benefit of pelabresib (CPI-0610) in combination with ruxolitinib in JAK-inhibitor treatment naïve myelofibrosis patients: Interim efficacy subgroup analysis from Arm 3 of MANIFEST Phase 2 study (Abstract Code: EP1085) 

TITLE: BET inhibitor pelabresib decreases inflammatory cytokines, improves bone marrow fibrosis and function, and demonstrates clinical response irrespective of mutation status in myelofibrosis patients (Abstract Code: EP1080) 

Date and Time: June 11, 9:00 AM CEST/ 3:00 AM EDT


MANIFEST is an open-label Phase 2 clinical trial of pelabresib (CPI-0610) in patients with myelofibrosis (MF), a rare cancer of the bone marrow that disrupts the body’s normal production of blood cells. Constellation is evaluating pelabresib in combination with ruxolitinib in JAK-inhibitor-naïve MF patients (Arm 3), with a primary endpoint of the proportion of patients with a ≥35% spleen volume reduction from baseline (SVR35) after 24 weeks of treatment. Constellation Pharmaceuticals is also evaluating pelabresib either as a monotherapy in patients who are resistant to, intolerant of, or ineligible for ruxolitinib and no longer on the drug (Arm 1), or as add-on therapy in combination with ruxolitinib in patients with a sub-optimal response to ruxolitinib or MF progression (Arm 2). Patients in Arms 1 and 2 are being stratified based on TD status. The primary endpoint for the patients in cohorts 1A and 2A, who were TD at baseline, is conversion to transfusion independence for 12 consecutive weeks. The primary endpoint for patients in cohorts 1B and 2B, who were not TD at baseline, is the proportion of patients with a ≥35% spleen volume reduction from baseline after 24 weeks of treatment. 

About Constellation Pharmaceuticals 

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor pelabresib for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of advanced malignancies. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the Company’s plans, strategies and prospects for its business and statements regarding the development status of the Company’s product candidates, the timing of availability of clinical trial data and the Company’s ability to fund its operations until mid-2023. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with: the Company’s ability to obtain and maintain necessary approvals from the FDA and other regulatory authorities; the Company’s ability to continue to advance its product candidates in clinical trials; whether preliminary or interim data from a clinical trial will be predictive of the final results of the trial; replication in later clinical trials positive results found in preclinical studies and early-stage clinical trials of pelabresib (CPI-0610), CPI-1205 and CPI-0209; the Company’s ability to advance the development of its product candidates under the timelines it anticipates, or at all, in current and future clinical trials; the Company’s ability to obtain, maintain, or protect intellectual property rights related to its product candidates; manage expenses; the Company’s ability to raise the substantial additional capital needed to achieve its business objectives; the COVID-19 pandemic and general economic and market conditions; and whether the previously announced acquisition of the Company by MorphoSys AG will be consummated on a timely basis. CPI-0610, CPI-1205 and CPI-0209 are investigational therapies and have not been approved by the FDA (or any other regulatory authority). For a discussion of other risks and uncertainties, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties, and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. 


Kia Khaleghpour, Ph.D. 
Vice President, Investor Relations and Communications 
Constellation Pharmaceuticals 
+1 617-844-6859 
Helen O’Gorman  
FTI Consulting  
+1 718-408-0800   

AVCO – Avalon GloboCare to Present at the Noble Capital Markets Investor Forum During the 16th Annual World Stem Cell Summit on June 17, 2021

FREEHOLD, N.J., June 11, 2021 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced that it will be presenting at the Noble Capital Markets Investor Forum during the 16th Annual World Stem Cell Summit to be held virtually on June 14-18, 2021.

David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer of Avalon GloboCare will present on Thursday, June 17th at 3:00 PM Eastern Daylight Time.

The presentation can be accessed in two ways: by registering for the full World Stem Cell Summit www.worldstemcellsummit.com, or by registering at no cost for the Investor Forum at www.channelchek.com, the investor portal created by Noble. The video webcast will be later archived on Channelchek as part of its C-Suite Series www.channelchek.com/c-suite, and on its YouTube channel. www.youtube.com/channelchek.

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.

For the latest updates on Avalon GloboCare’s developments, please follow our twitter at @avalongc_avco

About The World Stem Cell Summit

Produced by the nonprofit Regenerative Medicine Foundation (RMF), the 2021 Summit is the most inclusive and expansive interdisciplinary networking and partnering meeting in the stem cell translation and regenerative medicine field. With the overarching purpose of fostering biomedical research, funding and investments targeting cures, the Summit is the single conference serving the diverse ecosystem of regenerative medicine stakeholders. Combined with the WFIRM & RMF Regenerative Medicine Essentials Course, the Summit provides distinctive educational and futuristic experiences through which all participants collect opportunities, become inspired and flourish.

About Noble Capital Markets, Inc.

Noble Capital Markets (“Noble”) is a research driven boutique investment bank that has supported small & microcap companies since 1984. As a FINRA and SEC licensed broker dealer Noble provides institutional-quality equity research, merchant and investment banking, wealth management and order execution services. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the last decade. In 2018 Noble launched www.channelchek.com – a new investment community dedicated exclusively to small and micro-cap companies and their industries. Channelchek is tailored to meet the needs of self-directed investors and financial professionals. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 6,000 emerging growth companies are listed on the site, with growing content including webcasts, podcasts, and balanced news.

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.

Contact Information: 
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304

TTOO – World's Leading Proxy Advisory Firms ISS and Glass Lewis Recommend T2 Biosystems Stockholders Vote “FOR” the Charter Amendment Proposal – To Increase the Number of Authorized Shares of Common Stock

LEXINGTON, Mass., June 11, 2021 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that leading proxy advisory firms Institutional Shareholder Services Inc. (ISS) and Glass Lewis and Co., LLC (Glass Lewis), in addition to the Company’s Board of Directors, have recommended that T2 Biosystems stockholders vote in favor of the proposal to amend the Company’s Certification of Incorporation to increase the number of authorized shares of common stock (the “Charter Amendment Proposal”) at the upcoming annual stockholder meeting to be held on June 25, 2021.

T2 Biosystems’ President and CEO, John Sperzel, has previously released a statement communicating to stockholders the importance of this year’s proposals and their potential impact on the Company. The video statement can be found on the Investor Relations section of the Company’s website at investors.t2biosystems.com.

T2 Biosystems, Inc. will be holding its Annual Meeting virtually on June 25, 2021 at 9:00 a.m. Eastern Time at www.virtualshareholdermeeting.com/TTOO2021. T2 Biosystems’ stockholders of record as of April 28, 2021 are entitled to vote at the Annual Meeting. However, all stockholders are encouraged to vote ahead of the meeting, even if you are planning to attend.

T2 Biosystems’ definitive proxy materials, 2020 Annual Report to Stockholders and other relevant information can be found at www.sec.gov.

If you have any questions about how to vote your shares, or need additional assistance, please contact our proxy solicitor, MacKenzie Partners, toll-free at 1-800-322-2885.

About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the stockholder proposals and their potential impact, as well as statements that include the words “expect,” “intend,” “plan”, “believe”, “project”, “forecast”, “estimate,” “may,” “should,” “anticipate,” and similar statements of a future or forward looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the U.S. Securities and Exchange Commission, or SEC, on March 31, 2021, and other filings the Company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Important Information
The Company, its directors, director nominees and certain of its executive officers are participants in the solicitation of proxies from stockholders in respect of the Annual Meeting. The Company has filed a definitive proxy statement and associated proxy card in connection with the solicitation of proxies for the Annual Meeting with the SEC. Details concerning the nominees of the Company’s board of directors for election at the Annual Meeting are set forth in the definitive proxy statement. BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY’S DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO, AS THEY CONTAIN IMPORTANT INFORMATION. Information regarding the identity of the Company’s participants and their respective interests in the matters to be voted on at the Annual Meeting, by security holdings or otherwise, are set forth in the definitive proxy statement and other documents filed with the SEC in connection with the Annual Meeting. Investors and stockholders can obtain a copy of the definitive proxy statement and other documents filed by the Company free of charge from the SEC’s website at www.sec.gov. The Company’s stockholders can also obtain, without charge, a copy of the definitive proxy statement and other relevant filed documents from the “SEC Filings” section of the Company’s website at www.t2biosystems.com

Media Contact:
Gina Kent, Vault Communications

Investor Contact:
Philip Trip Taylor, Gilmartin Group